Adjuvant treatment of high-risk melanoma - cost-effectiveness analysis of treatment options for BRAF 600 mutated tumors.

Steffen WahlerAlfred MüllerSabine FuchsJohann-Matthias von der Schulenburg

Published in: Health economics review (2022)

Both dabrafenib/trametinib and nivolumab turned out to be cost effective within internationally accepted Incremental Cost Effectiveness Ratio (ICER) thresholds with comparable cost effectiveness ratios.

Keyphrases

early stage
combination therapy